PDF icon PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · South Asian J Cancer 2024; 13(04): 281-286
DOI: 10.1055/s-0045-1802564
Review Article
Chemotherapy

Adjuvant Chemotherapy in Colon Cancer: Simple is Better… Less is More

Prasad Narayanan
1   Department of Medical Oncology, Cytecare Hospital, Bengaluru, Karnataka, India
,
Shyam Aggarwal
2   Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India
,
Manish Singhal
3   Department of Medical Oncology, Indraprastha Apollo Hospital, New Delhi, India
,
Vamshi Krishna
4   Department of Medical Oncology, AIG Hospital, Hyderabad, Telangana, India
,
A. K. Rathi
5   Department of Radiation Oncology, Lok Nayak Hospital, New Delhi, India
,
Brig H. P. Singh
6   Department of Medical Oncology, Park Hospital, Mohali, Punjab, India
,
Atul Sharma
7   Department of Medical Oncology, Max Superspeciality Hospital, New Delhi, India
,
J. B. Sharma
8   Department of Medical Oncology, Action Cancer Hospital, New Delhi, India
,
Amit Bhargava
9   Department of Medical Oncology, Fortis Hospital, New Delhi, India
,
P. Suresh
10   Department of Medical Oncology, Army Hospital RR, New Delhi, India
,
Meenu Walia
7   Department of Medical Oncology, Max Superspeciality Hospital, New Delhi, India
,
H. S. Darling
11   Department of Medical Oncology, Air Force Hospital, Jorhat, Assam, India
,
K. Medhi
12   Department of Medical Oncology, Batra Hospital, New Delhi, India
,
Kumardeep Dutta
7   Department of Medical Oncology, Max Superspeciality Hospital, New Delhi, India
,
Sajjan Singh Rajpurohit
13   Department of Medical Oncology, BLK Max Superspeciality Hospital, New Delhi, India
,
Prashant Mehta
14   Department of Medical Oncology, Amrita Hospital, Faridabad, Haryana, India
,
Vikas Goswami
7   Department of Medical Oncology, Max Superspeciality Hospital, New Delhi, India
,
Saumitra Rawat
15   Department of Surgical Gastroenterology, Sir Ganga Ram Hospital, New Delhi, India
,
C. Selvasekar
16   Clinical Services & Specialist Surgery, The Christie NHS Foundation Trust, Manchester, United Kingdom
,
Purvish M. Parikh
17   Department of Clinical Hematology, Sri Ram Cancer Center, Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar aufeRef
  Lizenzen und Reprints
Preview

Abstract

A significant number of patients with colorectal cancer (CRC) benefit from adjuvant therapy. While 6 months of FOLFOX is standard of care, newer regimens like CAPOX and SOX allow for shorter durations. Trials of importance include SCOT (U.K., Denmark, Spain, Sweden, Australia, New Zealand), TOSCA (Italy), Alliance/SWOG80702 (U.S., Canada), IDEA (France), ACHIEVE (Japan), and HORG (Greece). Management recommendation is also based on patient preferences, dividing them into fighters and fatalists. Better patient selection is possible with the use of novel molecular-based biomarkers and circulating tumor deoxyribonucleic acid monitoring of minimal residual disease. There also needs to be special consideration for the geriatric patients—especially due to their limited mobility, comorbidities, and polypharmacy.

Keywords

overall survival - toxicity - drug metabolism - geriatric patients - ctDNA - MRD


Publikationsverlauf

Artikel online veröffentlicht:
14. Februar 2025

© 2025. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Labianca R, Nordlinger B, Beretta GD. et al; ESMO Guidelines Working Group. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl. 06) vi64-vi72
    CrossrefPubMedSuche in Google Scholar
  • 2 Schmoll HJ, Tabernero J, Maroun J. et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III Special article Annals of Oncology 1106 | Sobrero et al. Volume 29 | Issue 5 | 2018 colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol 2015; 33 (32) 3733-3740
    PubMedSuche in Google Scholar
  • 3 André T, Boni C, Navarro M. et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27 (19) 3109-3116
    CrossrefPubMedSuche in Google Scholar
  • 4 Haller DG, Tabernero J, Maroun J. et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29 (11) 1465-1471
    CrossrefPubMedSuche in Google Scholar
  • 5 Kidwell KM, Yothers G, Ganz PA. et al. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer 2012; 118 (22) 5614-5622
    CrossrefPubMedSuche in Google Scholar
  • 6 Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003; 30 (4, Suppl 15): 5-13
    CrossrefPubMedSuche in Google Scholar
  • 7 Shi Q, Sobrero A, Shields AF. et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): the IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. J Clin Oncol 2017; 35: Abstrct LBA1
    CrossrefSuche in Google Scholar
  • 8 Grothey A, Sobrero AF, Meyerhardt JA. et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): updated results of IDEA (International Duration Evaluation of Adjuvant Chemotherapy). Ann Oncol 2017 ;28:Abstract LBA21_PR
    Suche in Google Scholar
  • 9 Iveson T, Kerr R, Saunders M. et al. Updated results of the SCOT study: an international phase III randomised (1: 1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer. Annals Oncol 2017; 28 (Suppl. 05) Abstract LBA22
    Suche in Google Scholar
  • 10 Lonardi S, Sobrero A, Rosati G. et al; TOSCA (Three or Six Colon Adjuvant) Investigators. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. Ann Oncol 2016; 27 (11) 2074-2081
    CrossrefPubMedSuche in Google Scholar
  • 11 Grothey A, Sobrero AF, Shields AF. et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018; 378 (13) 1177-1188
    CrossrefPubMedSuche in Google Scholar
  • 12 Sobrero A, Grothey A, Iveson T. et al. The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?. Ann Oncol 2018; 29 (05) 1099-1107
    CrossrefPubMedSuche in Google Scholar
  • 13 Meyerhardt JA, Shi Q, Fuchs CS. et al. Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage III colon cancer: the CALGB/SWOG 80702 (Alliance) randomized clinical trial. JAMA 2021; 325 (13) 1277-1286
    CrossrefPubMedSuche in Google Scholar
  • 14 Sobrero AF, Andre T, Meyerhardt JA. Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration. J Clin Oncol 2020; 38 (15, suppl): 4004-4004
    CrossrefSuche in Google Scholar
  • 15 Yoshino T, Oki E, Misumi T. et al. Final analysis of 3 versus 6 months of adjuvant oxaliplatin and fluoropyrimidine-based therapy in patients with stage III colon cancer: the randomized phase III ACHIEVE trial. J Clin Oncol 2022; 40 (29) 3419-3429
    CrossrefPubMedSuche in Google Scholar
  • 16 Souglakos J, Boukovinas I, Kakolyris S. et al. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project. Ann Oncol 2019; 30 (08) 1304-1310
    CrossrefPubMedSuche in Google Scholar
  • 17 Petrelli F, Labianca R, Zaniboni A. et al. Assessment of duration and effects of 3 vs 6 months of adjuvant chemotherapy in high-risk stage II colorectal cancer: a subgroup analysis of the TOSCA randomized clinical trial. JAMA Oncol 2020; 6 (04) 547-551
    CrossrefPubMedSuche in Google Scholar
  • 18 Gögenur M, Rosen AW, Iveson T. et al. Time from colorectal cancer surgery to adjuvant chemotherapy: post hoc analysis of the SCOT randomized clinical trial. JAMA Surg 2024; 159 (08) 865-871
    CrossrefPubMedSuche in Google Scholar
  • 19 Loree JM, Sha A, Soleimani M. et al. Survival impact of CAPOX versus FOLFOX in the adjuvant treatment of stage III colon cancer. Clin Colorectal Cancer 2018; 17 (02) 156-163
    CrossrefPubMedSuche in Google Scholar
  • 20 Loree JM, Mulder KE, Ghosh S, Spratlin JL. CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer. Clin Colorectal Cancer 2014; 13 (03) 172-177
    CrossrefPubMedSuche in Google Scholar
  • 21 Degirmencioglu S, Tanrıverdi O, Demiray AG, Senol H, Dogu GG, Yaren A. Retrospective comparison of efficacy and safety of CAPOX and FOLFOX regimens as adjuvant treatment in patients with stage III colon cancer. J Int Med Res 2019; 47 (06) 2507-2515
    CrossrefPubMedSuche in Google Scholar
  • 22 Aitini E, Rossi A, Morselli P. et al. Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer. Cancer Manag Res 2012; 4: 99-103
    PubMedSuche in Google Scholar
  • 23 Ramaswamy A, Kothari R, Desouza A. et al. Adjuvant chemotherapy in stage II-III operated colon cancer patients from a nontrial cohort in a low colon cancer prevalence country with predominant use of modified CAPOX. South Asian J Cancer 2019; 8 (03) 160-165
    Thieme ConnectPubMedSuche in Google Scholar
  • 24 Georgilis E, Gavriatopoulou M, Tsilimigras DI, Malandrakis P, Theodosopoulos T, Ntanasis-Stathopoulos I. Optimizing adjuvant therapy after surgery for colorectal cancer liver metastases: a systematic review. J Clin Med 2023; 12 (06) 2401
    CrossrefPubMedSuche in Google Scholar
  • 25 Offermans K, Jenniskens JCA, Simons CCJM. et al. Association between adjuvant therapy and survival in colorectal cancer patients according to metabolic Warburg-subtypes. J Cancer Res Clin Oncol 2023; 149 (09) 6271-6282
    CrossrefPubMedSuche in Google Scholar
  • 26 Matsuda A, Yamada T, Takahashi G. et al. Significance of adjuvant chemotherapy for obstructive colorectal cancer after stent placement: a multicenter retrospective study. Anticancer Res 2024; 44 (06) 2737-2745
    CrossrefPubMedSuche in Google Scholar
  • 27 Williams CJM, Gray R, Hills RK. et al. Evaluation of CD3 and CD8 T-cell immunohistochemistry for prognostication and prediction of benefit from adjuvant chemotherapy in early-stage colorectal cancer within the QUASAR trial. J Clin Oncol 2024; 42 (29) 3430-3442
    CrossrefPubMedSuche in Google Scholar
  • 28 Jiang W, Wang H, Dong X. et al. Pathomics signature for prognosis and chemotherapy benefits in stage III colon cancer. JAMA Surg 2024; 159 (05) 519-528
    CrossrefPubMedSuche in Google Scholar
  • 29 Yang L, Yang J, Kleppe A, Danielsen HE, Kerr DJ. Personalizing adjuvant therapy for patients with colorectal cancer. Nat Rev Clin Oncol 2024; 21 (01) 67-79
    CrossrefPubMedSuche in Google Scholar
  • 30 Okamoto K, Nozawa H, Emoto S, Murono K, Sasaki K, Ishihara S. Adjuvant chemotherapy for elderly patients with colorectal cancer: a single-centre observational study in Japan. J Chemother 2024; 36 (04) 319-328
    CrossrefPubMedSuche in Google Scholar
  • 31 Zhang L, Li Q, Hu C, Zhang Z, She J, Shi F. Real-world analysis of survival benefit of surgery and adjuvant therapy in elderly patients with colorectal cancer. Sci Rep 2023; 13 (01) 14866
    CrossrefPubMedSuche in Google Scholar
  • 32 Sharma BB, Rai K, Blunt H, Zhao W, Tosteson TD, Brooks GA. Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis. Oncologist 2021; 26 (12) 1008-1016
    CrossrefPubMedSuche in Google Scholar
  • 33 Cura Y, Sánchez-Martín A, Márquez-Pete N. et al. Association of single-nucleotide polymorphisms in capecitabine bioactivation pathway with adjuvant therapy safety in colorectal cancer patients. Pharmaceutics 2023; 15 (11) 2548
    CrossrefPubMedSuche in Google Scholar
  • 34 Naushad SM, Hussain T, Alrokayan SA, Kutala VK. Pharmacogenetic profiling of dihydropyrimidine dehydrogenase (DPYD) variants in the Indian population. J Gene Med 2021; 23 (01) e3289
    CrossrefPubMedSuche in Google Scholar
  • 35 Pavithran K, Ariyannur P, Jayamohanan H. et al. Dihydropyrimidine dehydrogenase deficiency in patients treated with 5FU or capecitabine based regimens: a single center experience from South India. JCO 2021; 39 (15)
    CrossrefSuche in Google Scholar
  • 36 Patil VM, Chougule A, Noronha V. et al. DPYD mutation in Indian patients. Clin Oncol (R Coll Radiol) 2019; 31 (10) 732-733
    CrossrefPubMedSuche in Google Scholar
  • 37 Vail E, Choubey AP, Alexander HR. et al. Recurrence-free survival dynamics following adjuvant chemotherapy for resected colorectal cancer: a systematic review of randomized controlled trials. Cancer Med 2024; 13 (01) e6884
    CrossrefPubMedSuche in Google Scholar
  • 38 Nakamura Y, Watanabe J, Akazawa N. et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med 2024; 30 (11) 3272-3283
    CrossrefPubMedSuche in Google Scholar
  • 39 Chidharla A, Rapoport E, Agarwal K. et al. Circulating tumor DNA as a minimal residual disease assessment and recurrence risk in patients undergoing curative-intent resection with or without adjuvant chemotherapy in colorectal cancer: a systematic review and meta-analysis. Int J Mol Sci 2023; 24 (12) 10230
    CrossrefPubMedSuche in Google Scholar
  • 40 Burley N, Lee Y, Liu L. et al. ctDNA-guided adjuvant immunotherapy in colorectal cancer. Immunotherapy 2024; 1-6 ; Epub ahead of print
    CrossrefPubMedSuche in Google Scholar